Bất thường đông máu ở bệnh nhân ghép tế bào gốc tạo máu tại Viện Huyết học - Truyền máu Trung ương giai đoạn 2021-2022=Coagulation abnormalities in patients undergoing hematopoietic stem cell transplantation at National Institute of Hematology and Blood Transfusion from 2021-2022

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Phan Thu Hường Đào, Thị Thuý Đỗ, Thị Thanh Hoàng, Bá Khanh Nguyễn, Thị Minh Tâm Nguyễn, Thị Nhài Nguyễn, Thị Hồng Trần, Thị Thanh Bình Võ

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.661-668

Bộ sưu tập: Metadata

ID: 478343

Thêm vào giỏ

Mô tả một số bất thường đông máu ở bệnh nhân ghép tế bào gốc tạo máu tại Viện Huyết học-Truyền máu Trung ương giai đoạn 2021-2022
Đối tượng: 58 bệnh nhân được ghép tế bào gốc tự thân (19 ca) và đồng loài (39 ca). Phương pháp: mô tả loạt ca bệnh, chọn mẫu toàn bộ. Kết quả: Bất thường đông máu thường xuất hiện vào tuần thứ 1 và tuần thứ 2 sau ghép
tỷ lệ gặp PT-INR >
1,25 sau ghép là 61,2%, thời gian xuất hiện trung vị là 10 ngày (4-50 ngày) và phục hồi sau trung vị 7 ngày (2-63 ngày)
yếu tố đông máu rối loạn nhiều nhất là yếu tố VII (định lượng trung bình 31,1±11,4%), yếu tố X (định lượng trung bình 53,2±13%) còn các yếu tố khác ít bị ảnh hưởng
yếu tố liên quan đến tăng tỷ lệ xuất hiện bất thường đông máu gồm: ghép đồng loài, liều busulfan 12,8 mg/kg tương ứng thời gian dùng phenytoin 7 ngày, nuôi dưỡng qua đường tĩnh mạch. Kết luận: Ghép tế bào gốc tạo máu ở những nhóm sử dụng busulfan có thể ảnh hưởng đến diễn biến đông máu của một số nhóm bệnh nhân, cần có phương án theo dõi và dự phòng phù hợp với các đối tượng nguy cơ cao.Stem cell transplantation is an effective treatment for many hematological diseases. Coagulation related disorder is a possible complication that may happen during transplantation. Objective: To describe some coagulation abnormalities in patients undergoing hematopoietic stem cell transplantation at National Institute of Hematology and Blood Transfusion from 2021-2022. Subjects: 58 transplanted patients including 19 autologous and 39 allogeneic cases. Methods: Case series descriptive study, total population sampling. Results: Coagulation abnormalities commonly occured in the first and second week after transplantation
the rate patients with PT-INR >
1,25 was 61.2%, median time to event was 10 days (4-50 days) and recovered after a median of 7 days (2-63 days)
the most common abnormal coagulation factors were Factor VII (medium level 31.1 ± 11.4%) and Factor X (medium level 53.2 ± 13%), other factors were not significantly involved
factors related to higher risk of coagulation abnormalities included: allogeneic transplant, busulfan dose of 12.8mg/kg with phenitoin used for 7 days, parenteral nutrition. Conclusion: Hematopoietic stem cell transplantation with busulfan may affect coagulation status in some patient groups, a proper solution for monitoring and prophylaxis is needed for high risk cases.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR